Subscribe to the our newsletter to receive latest news straight to your inbox.
Confluence Discovery Technologies has emerged as a pivotal player in the biotech and pharmaceutical sectors, particularly in immunology and drug discovery. The company’s contribution to therapeutic advancements, coupled with its acquisition by Aclaris Therapeutics, positions it as a subject of significant interest in the biomedical landscape. This article examines the valuation, strategic importance, and entities…
Confluence Discovery Technologies has emerged as a pivotal player in the biotech and pharmaceutical sectors, particularly in immunology and drug discovery. The company’s contribution to therapeutic advancements, coupled with its acquisition by Aclaris Therapeutics, positions it as a subject of significant interest in the biomedical landscape. This article examines the valuation, strategic importance, and entities associated with Confluence Discovery Technologies, providing an in-depth understanding of its operations and market relevance.
Confluence Discovery Technologies is a biotechnology company specializing in drug discovery and development, with a focus on immunological and inflammatory diseases. Founded in 2010 and headquartered in St. Louis, Missouri, the company has significantly contributed to therapies addressing cancer, autoimmune diseases, and skin disorders.
Understanding Confluence’s financial foundation provides insights into its valuation. The company received significant funding prior to its acquisition, underlining its market potential.
Confluence Discovery Technologies raised $10 million in seed and early-stage funding from investors such as:
In 2017, Confluence was acquired by Aclaris Therapeutics, a biopharmaceutical company, for an upfront payment of $20 million, with additional milestones potentially increasing the total value of the deal【7】【8】.
Post-acquisition, Confluence’s core capabilities in drug discovery serve as a key revenue driver for Aclaris, contributing through:
While specific net worth figures remain undisclosed, the $20 million acquisition and Confluence’s role in advancing Aclaris’ portfolio indicate a valuation aligned with high-growth biotech startups.
Confluence’s innovative drug discovery programs serve as its cornerstone.
Aclaris aims to extend Confluence’s pipeline into adjacent therapeutic categories, leveraging its infrastructure and expertise.
Confluence Discovery Technologies exemplifies the growing role of niche biotech firms in the broader pharmaceutical ecosystem.
Their research has advanced understanding and treatment of immune-related disorders, addressing unmet medical needs.
Based in St. Louis, Confluence has contributed to the city’s emergence as a hub for biomedical innovation.
Collaborative projects with universities and industry partners enhance the company’s credibility and output.
Confluence’s integration into Aclaris highlights its strategic importance and potential to drive industry growth.
Aspect | Details |
---|---|
Founded | 2010 |
Headquarters | St. Louis, Missouri |
Core Areas | Drug discovery, autoimmune diseases, cancer therapies |
Funding | $10 million (Epidarex Capital, Mercury Fund) |
Acquisition | By Aclaris Therapeutics for $20 million |
Lead Programs | CDD-450, Soft JAK inhibitors, ITK inhibitors |
Industry Impact | Contributions to immunology and regional innovation |
Confluence Discovery Technologies exemplifies innovation and strategic growth in the biotech industry. Its focus on immunological therapies and drug discovery has not only advanced medical science but also positioned it as a valuable asset to Aclaris Therapeutics. As the industry evolves, Confluence’s expertise and pipeline expansion will likely continue to shape its valuation and influence.
Q: What is Confluence Discovery Technologies’ net worth?
A: Specific figures for net worth are undisclosed, but its $20 million acquisition by Aclaris Therapeutics and role in drug discovery underline its significant valuation.
Q: What does Confluence specialize in?
A: The company focuses on drug discovery for inflammatory, autoimmune, and cancer-related diseases.
Q: Why was Confluence acquired by Aclaris Therapeutics?
A: Aclaris aimed to enhance its pipeline in dermatology and adjacent therapeutic areas using Confluence’s expertise.
Q: What are Confluence’s key programs?
A: Lead programs include CDD-450, soft JAK inhibitors, and ITK inhibitors.
Q: How does Confluence impact the biotech industry?
A: It advances immunological therapies, fosters regional innovation, and contributes to industry growth.
#BiotechValuation #DrugDiscovery #Immunology #AclarisTherapeutics #BiomedicalInnovation